Understanding the HIV/STI risks and prevention needs of men who have sex with men in Nairobi, Kenya
View/ Open
Date
2005Author
Onyango-Ouma, W
Birungi, H.
Geibel., S
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Background
Improving access to paediatric HIV treatment requires large-scale antiretroviral treatment
programmes and medication adapted to infants and children’s needs. The World Health
Organisation recommends lopinavir/ritonavir plus two nucleoside reverse transcriptase
inhibitors as first-line treatment for all HIV-infected children younger than three years, usually
given as a syrup. A pellet formulation (i.e. tiny cylinders of compressed medication put in
capsules) was developed to overcome the syrup formulation’s disadvantages such as bitterness,
toxicity and cold storage. This study assessed multi-level factors influencing caregivers’
acceptance of and adherence to lopinavir/ritonavir pellets as well as their underlying
mechanisms.
Publisher
University of Nairobi Institute of African Studies
Collections
The following license files are associated with this item: